LY3885125
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 06, 2025
A Study of LY3885125 in Participants with Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
(clinicaltrials.gov)
- P1 | N=49 | Terminated | Sponsor: Eli Lilly and Company | N=112 ➔ 49 | Active, not recruiting ➔ Terminated; Participants were not dosed in Part B as per the protocol, the patient population will be refined and new outcome measures will be applied in a separate study.
Enrollment change • Trial termination • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease
December 20, 2024
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
(clinicaltrials.gov)
- P1 | N=112 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Dyslipidemia • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease
1 to 2
Of
2
Go to page
1